FindTrial
Sign In

Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

Clinical Study Evaluating the Effectiveness of Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03925701
Enrollment
120
Registered
2019-04-24
Start date
2019-04-01
Completion date
2028-12-31
Last updated
2019-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dm

Brief summary

Clinical study evaluating vildagliptin versus vildagliptin/metformin on NAFLD with DM.

Detailed description

Clinical study evaluating vildagliptin versus vildagliptin/metformin on nonalcoholic fatty liver disease with DM.

Interventions

DRUGVildagliptin

vildagliptin twice daily

DRUGvildagliptin\metformin

vildagliptin\\metformin twice daily

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* NAFLD and type 2 DM

Exclusion criteria

* Viral hepatitis. * Child score more than 6. * renal impairment.

Design outcomes

Primary

MeasureTime frameDescription
number of patients with improved nafld and insulin resistance6 monthsnumber of patients showing improved nafld and insulin resistance

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026